Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment

Jin Yang, Konstantinos Savvatis, Jong Seok Kang, Peidong Fan, Hongyan Zhong, Karen Schwartz, Vivian Barry, Amanda Mikels-Vigdal, Serge Karpinski, Dmytro Kornyeyev, Joanne Adamkewicz, Xuhui Feng, Qiong Zhou, Ching Shang, Praveen Kumar, Dillon Phan, Mario Kasner, Begonã López, Javier Diez, Keith C. WrightRoxanne L. Kovacs, Peng-Sheng Chen, Thomas Quertermous, Victoria Smith, Lina Yao, Carsten Tschöpe, Ching-Pin Chang

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Interstitial fibrosis plays a key role in the development and progression of heart failure. Here, we show that an enzyme that crosslinks collagen-Lysyl oxidase-like 2 (Loxl2)-is essential for interstitial fibrosis and mechanical dysfunction of pathologically stressed hearts. In mice, cardiac stress activates fibroblasts to express and secrete Loxl2 into the interstitium, triggering fibrosis, systolic and diastolic dysfunction of stressed hearts. Antibody-mediated inhibition or genetic disruption of Loxl2 greatly reduces stress-induced cardiac fibrosis and chamber dilatation, improving systolic and diastolic functions. Loxl2 stimulates cardiac fibroblasts through PI3K/AKT to produce TGF-β2, promoting fibroblast-to-myofibroblast transformation; Loxl2 also acts downstream of TGF-β2 to stimulate myofibroblast migration. In diseased human hearts, LOXL2 is upregulated in cardiac interstitium; its levels correlate with collagen crosslinking and cardiac dysfunction. LOXL2 is also elevated in the serum of heart failure (HF) patients, correlating with other HF biomarkers, suggesting a conserved LOXL2-mediated mechanism of human HF.

Original languageEnglish (US)
Article number13710
JournalNature Communications
Volume7
DOIs
StatePublished - Dec 14 2016

Fingerprint

Protein-Lysine 6-Oxidase
fibrosis
interstitials
oxidase
Fibrosis
Heart Failure
Myofibroblasts
fibroblasts
Fibroblasts
collagens
Therapeutics
Phosphatidylinositol 3-Kinases
Dilatation
Heart Diseases
biomarkers
Collagen
Biomarkers
crosslinking
antibodies
progressions

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Yang, J., Savvatis, K., Kang, J. S., Fan, P., Zhong, H., Schwartz, K., ... Chang, C-P. (2016). Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nature Communications, 7, [13710]. https://doi.org/10.1038/ncomms13710

Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. / Yang, Jin; Savvatis, Konstantinos; Kang, Jong Seok; Fan, Peidong; Zhong, Hongyan; Schwartz, Karen; Barry, Vivian; Mikels-Vigdal, Amanda; Karpinski, Serge; Kornyeyev, Dmytro; Adamkewicz, Joanne; Feng, Xuhui; Zhou, Qiong; Shang, Ching; Kumar, Praveen; Phan, Dillon; Kasner, Mario; López, Begonã; Diez, Javier; Wright, Keith C.; Kovacs, Roxanne L.; Chen, Peng-Sheng; Quertermous, Thomas; Smith, Victoria; Yao, Lina; Tschöpe, Carsten; Chang, Ching-Pin.

In: Nature Communications, Vol. 7, 13710, 14.12.2016.

Research output: Contribution to journalArticle

Yang, J, Savvatis, K, Kang, JS, Fan, P, Zhong, H, Schwartz, K, Barry, V, Mikels-Vigdal, A, Karpinski, S, Kornyeyev, D, Adamkewicz, J, Feng, X, Zhou, Q, Shang, C, Kumar, P, Phan, D, Kasner, M, López, B, Diez, J, Wright, KC, Kovacs, RL, Chen, P-S, Quertermous, T, Smith, V, Yao, L, Tschöpe, C & Chang, C-P 2016, 'Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment', Nature Communications, vol. 7, 13710. https://doi.org/10.1038/ncomms13710
Yang J, Savvatis K, Kang JS, Fan P, Zhong H, Schwartz K et al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nature Communications. 2016 Dec 14;7. 13710. https://doi.org/10.1038/ncomms13710
Yang, Jin ; Savvatis, Konstantinos ; Kang, Jong Seok ; Fan, Peidong ; Zhong, Hongyan ; Schwartz, Karen ; Barry, Vivian ; Mikels-Vigdal, Amanda ; Karpinski, Serge ; Kornyeyev, Dmytro ; Adamkewicz, Joanne ; Feng, Xuhui ; Zhou, Qiong ; Shang, Ching ; Kumar, Praveen ; Phan, Dillon ; Kasner, Mario ; López, Begonã ; Diez, Javier ; Wright, Keith C. ; Kovacs, Roxanne L. ; Chen, Peng-Sheng ; Quertermous, Thomas ; Smith, Victoria ; Yao, Lina ; Tschöpe, Carsten ; Chang, Ching-Pin. / Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. In: Nature Communications. 2016 ; Vol. 7.
@article{e5afda92fc8e44188a1610c9975df0ee,
title = "Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment",
abstract = "Interstitial fibrosis plays a key role in the development and progression of heart failure. Here, we show that an enzyme that crosslinks collagen-Lysyl oxidase-like 2 (Loxl2)-is essential for interstitial fibrosis and mechanical dysfunction of pathologically stressed hearts. In mice, cardiac stress activates fibroblasts to express and secrete Loxl2 into the interstitium, triggering fibrosis, systolic and diastolic dysfunction of stressed hearts. Antibody-mediated inhibition or genetic disruption of Loxl2 greatly reduces stress-induced cardiac fibrosis and chamber dilatation, improving systolic and diastolic functions. Loxl2 stimulates cardiac fibroblasts through PI3K/AKT to produce TGF-β2, promoting fibroblast-to-myofibroblast transformation; Loxl2 also acts downstream of TGF-β2 to stimulate myofibroblast migration. In diseased human hearts, LOXL2 is upregulated in cardiac interstitium; its levels correlate with collagen crosslinking and cardiac dysfunction. LOXL2 is also elevated in the serum of heart failure (HF) patients, correlating with other HF biomarkers, suggesting a conserved LOXL2-mediated mechanism of human HF.",
author = "Jin Yang and Konstantinos Savvatis and Kang, {Jong Seok} and Peidong Fan and Hongyan Zhong and Karen Schwartz and Vivian Barry and Amanda Mikels-Vigdal and Serge Karpinski and Dmytro Kornyeyev and Joanne Adamkewicz and Xuhui Feng and Qiong Zhou and Ching Shang and Praveen Kumar and Dillon Phan and Mario Kasner and Begon{\~a} L{\'o}pez and Javier Diez and Wright, {Keith C.} and Kovacs, {Roxanne L.} and Peng-Sheng Chen and Thomas Quertermous and Victoria Smith and Lina Yao and Carsten Tsch{\"o}pe and Ching-Pin Chang",
year = "2016",
month = "12",
day = "14",
doi = "10.1038/ncomms13710",
language = "English (US)",
volume = "7",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment

AU - Yang, Jin

AU - Savvatis, Konstantinos

AU - Kang, Jong Seok

AU - Fan, Peidong

AU - Zhong, Hongyan

AU - Schwartz, Karen

AU - Barry, Vivian

AU - Mikels-Vigdal, Amanda

AU - Karpinski, Serge

AU - Kornyeyev, Dmytro

AU - Adamkewicz, Joanne

AU - Feng, Xuhui

AU - Zhou, Qiong

AU - Shang, Ching

AU - Kumar, Praveen

AU - Phan, Dillon

AU - Kasner, Mario

AU - López, Begonã

AU - Diez, Javier

AU - Wright, Keith C.

AU - Kovacs, Roxanne L.

AU - Chen, Peng-Sheng

AU - Quertermous, Thomas

AU - Smith, Victoria

AU - Yao, Lina

AU - Tschöpe, Carsten

AU - Chang, Ching-Pin

PY - 2016/12/14

Y1 - 2016/12/14

N2 - Interstitial fibrosis plays a key role in the development and progression of heart failure. Here, we show that an enzyme that crosslinks collagen-Lysyl oxidase-like 2 (Loxl2)-is essential for interstitial fibrosis and mechanical dysfunction of pathologically stressed hearts. In mice, cardiac stress activates fibroblasts to express and secrete Loxl2 into the interstitium, triggering fibrosis, systolic and diastolic dysfunction of stressed hearts. Antibody-mediated inhibition or genetic disruption of Loxl2 greatly reduces stress-induced cardiac fibrosis and chamber dilatation, improving systolic and diastolic functions. Loxl2 stimulates cardiac fibroblasts through PI3K/AKT to produce TGF-β2, promoting fibroblast-to-myofibroblast transformation; Loxl2 also acts downstream of TGF-β2 to stimulate myofibroblast migration. In diseased human hearts, LOXL2 is upregulated in cardiac interstitium; its levels correlate with collagen crosslinking and cardiac dysfunction. LOXL2 is also elevated in the serum of heart failure (HF) patients, correlating with other HF biomarkers, suggesting a conserved LOXL2-mediated mechanism of human HF.

AB - Interstitial fibrosis plays a key role in the development and progression of heart failure. Here, we show that an enzyme that crosslinks collagen-Lysyl oxidase-like 2 (Loxl2)-is essential for interstitial fibrosis and mechanical dysfunction of pathologically stressed hearts. In mice, cardiac stress activates fibroblasts to express and secrete Loxl2 into the interstitium, triggering fibrosis, systolic and diastolic dysfunction of stressed hearts. Antibody-mediated inhibition or genetic disruption of Loxl2 greatly reduces stress-induced cardiac fibrosis and chamber dilatation, improving systolic and diastolic functions. Loxl2 stimulates cardiac fibroblasts through PI3K/AKT to produce TGF-β2, promoting fibroblast-to-myofibroblast transformation; Loxl2 also acts downstream of TGF-β2 to stimulate myofibroblast migration. In diseased human hearts, LOXL2 is upregulated in cardiac interstitium; its levels correlate with collagen crosslinking and cardiac dysfunction. LOXL2 is also elevated in the serum of heart failure (HF) patients, correlating with other HF biomarkers, suggesting a conserved LOXL2-mediated mechanism of human HF.

UR - http://www.scopus.com/inward/record.url?scp=85006056554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006056554&partnerID=8YFLogxK

U2 - 10.1038/ncomms13710

DO - 10.1038/ncomms13710

M3 - Article

C2 - 27966531

AN - SCOPUS:85006056554

VL - 7

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 13710

ER -